IAM.US Iambic Therapeutics, Inc. Common Stock

Healthcare Biotechnology USA Stocks
13.10 USD
Close of Nov 15, 2026
9.60 25.00
Market cap
USD 621M
P/E
-
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is IAM.US undervalued?

Graham number

The Graham number of Iambic Therapeutics, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Iambic Therapeutics, Inc. Common Stock fundamental analysis

No fundamental analysis for Iambic Therapeutics, Inc. Common Stock yet.

Iambic Therapeutics, Inc. Common Stock stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Iambic Therapeutics, Inc. Common Stock

Iambic Therapeutics, Inc. operates as a biotechnology company that develops therapeutics from its AI discovery platform that optimizes target product profiles and drug candidates in the United States and Internationally. It offers products, such as IAM-1363, a selective HER2 inhibitor; IAM-K1, a KIF18A inhibitor; IAM217 (a KIF18A inhibitor) and IAM-C1, a CDK2/4 inhibitor; and services, including drug discovery platform and molecular superintelligence platform which includes …

Full company profile